The Oncology Institute delivered strong third quarter results, achieving $137 million in revenue—up 23% year-over-year—while marking its first month of adjusted EBITDA profitability as a public company.

• Pharmacy business surged 42% year-over-year, driving significant revenue growth.
• Achieved a $4.7 million improvement in adjusted EBITDA loss compared to Q3 2024, with expectations to reach overall profitability in Q4.
• Expanded partnership with Elevance Health, doubling the Medicare Advantage lives under capitation in under a year.
• Launched AI initiatives to enhance operational efficiency, potentially saving $2 million in operating expenses.
• Despite a recent cybersecurity incident affecting billing, operations remained largely unaffected, with strong cash reserves projected for Q4 and 2026.